IL319859A - Methods for treating spinal muscular atrophy - Google Patents

Methods for treating spinal muscular atrophy

Info

Publication number
IL319859A
IL319859A IL319859A IL31985925A IL319859A IL 319859 A IL319859 A IL 319859A IL 319859 A IL319859 A IL 319859A IL 31985925 A IL31985925 A IL 31985925A IL 319859 A IL319859 A IL 319859A
Authority
IL
Israel
Prior art keywords
methods
muscular atrophy
spinal muscular
treating spinal
treating
Prior art date
Application number
IL319859A
Other languages
Hebrew (he)
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of IL319859A publication Critical patent/IL319859A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL319859A 2022-10-14 2023-10-13 Methods for treating spinal muscular atrophy IL319859A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263416416P 2022-10-14 2022-10-14
US202263428348P 2022-11-28 2022-11-28
US202263434915P 2022-12-22 2022-12-22
PCT/US2023/076912 WO2024081932A1 (en) 2022-10-14 2023-10-13 Methods for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
IL319859A true IL319859A (en) 2025-05-01

Family

ID=88779222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319859A IL319859A (en) 2022-10-14 2023-10-13 Methods for treating spinal muscular atrophy

Country Status (10)

Country Link
US (1) US20240173325A1 (en)
EP (1) EP4601651A1 (en)
JP (1) JP2025534681A (en)
KR (1) KR20250084181A (en)
CN (1) CN120035443A (en)
AU (1) AU2023358525A1 (en)
IL (1) IL319859A (en)
MX (1) MX2025004248A (en)
TW (1) TW202423419A (en)
WO (1) WO2024081932A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015261046C1 (en) 2014-05-15 2019-07-25 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
MX2017005774A (en) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
EA038146B1 (en) 2015-09-15 2021-07-13 Сколар Рок, Инк. Anti-pro/latent-myostatin antibodies and uses thereof
EA201891420A1 (en) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
CN120554386A (en) 2018-10-19 2025-08-29 豪夫迈·罗氏有限公司 Novel pyrido[1,2-a]pyrimidin-4-one derivatives, preparations and preparation methods thereof
EP4013387A4 (en) * 2019-08-15 2023-09-27 Biogen MA Inc. Combination therapy for spinal muscular atrophy
EP4426306A1 (en) 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Novel combined administration

Also Published As

Publication number Publication date
EP4601651A1 (en) 2025-08-20
WO2024081932A1 (en) 2024-04-18
TW202423419A (en) 2024-06-16
AU2023358525A1 (en) 2025-04-10
CN120035443A (en) 2025-05-23
MX2025004248A (en) 2025-05-02
US20240173325A1 (en) 2024-05-30
KR20250084181A (en) 2025-06-10
JP2025534681A (en) 2025-10-17

Similar Documents

Publication Publication Date Title
GB202314527D0 (en) New treatment for pain
IL307937A (en) Treatment methods for muscular dystrophy
IL312753A (en) Gene therapy for spinal muscular atrophy
IL289745A (en) Methods of treating or preventing spinal muscular atrophy
IL319321A (en) Methods for treating obesity
EP4013387A4 (en) Combination therapy for spinal muscular atrophy
IL315403A (en) Mirdametinib treatment
EP4208255A4 (en) Methods for treating bone mineralization disorders
IL315480A (en) Compounds and methods for treating disease
LT4518970T (en) Use of myostatin inhibitor for treating spinal muscular atrophy
EP4048175A4 (en) Apparatuses and methods for correcting bone deformities
IL326452A (en) A new preparation for the treatment of spinal muscular atrophy
IL321850A (en) Compositions and methods for treating spinal muscular atrophy
IL320268A (en) Compounds and methods for improving health
EP4590289A4 (en) Muscle atrophy
CA3297342A1 (en) Methods for combination treatment of spinal muscular atrophy
CA3280354A1 (en) Compositions and methods for treating spinal muscular atrophy
HK40070509A (en) Methods of treating or preventing spinal muscular atrophy
CA229231S (en) Medical rehabilitation apparatus
HK40095665A (en) Methods for treating bone mineralization disorders
IL326390A (en) Compositions and methods for treating spinal muscular atrophy
GB202002038D0 (en) Compounds for treating bone disorders
HK40042254A (en) Methods of treating spinal muscular atrophy
IL315107A (en) Ampreloxetine for use for treating multiple system atrophy
CA3269698A1 (en) Methods for treating obesity